[Skip to Content]
[Skip to Content Landing]
Views 1,736
Citations 0
Health Agencies Update
December 24/31, 2019

US Sues Gilead, Alleging PrEP Drugs Infringe on HHS Patents

JAMA. 2019;322(24):2374. doi:10.1001/jama.2019.20561

On behalf of the Department of Health and Human Services (HHS), the United States recently sued Gilead Sciences and Gilead Sciences Ireland over their preexposure prophylaxis (PrEP) drugs.

The lawsuit, filed in federal district court in Delaware, alleges that Gilead has infringed on HHS patents stemming from groundbreaking, taxpayer-funded research at the Centers for Disease Control and Prevention (CDC). As a result, the complaint alleges, Gilead has reaped billions of dollars from the sale of Truvada and Descovy, which both contain emtricitabine and tenofovir.

×